Eli Lilly and Company (LLY): Price Target and June Short Interest Disclosure

Eli Lilly and Company (LLY) : The most positive equity analysts on Eli Lilly and Company (LLY) expects the shares to touch $116, whereas, the least positive believes that the stock will trade at $55 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $94.58 with an expected fluctuation of $15.96 from the mean.

Eli Lilly and Company (LLY), A drop of 110,727 shares or 1.2% was seen in the short interest of Eli Lilly & Company. Even as the interest dropped from 9,269,686 shares on June 15,2016 to 9,158,959 shares on June 30,2016, the days to cover came in at 2. The updated interest stood at 0.9% of the stocks floats. The stock has seen an average daily volume of 5,974,288 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Leerink Swann maintains its rating on Eli Lilly and Company (NYSE:LLY). The global brokerage major raises the current price target from $96 per share to $101 per share. Analysts at the Leerink Swann have a current rating of Outperform on the shares. The rating by the firm was issued on May 2, 2016.


Eli Lilly and Company (NYSE:LLY): stock turned positive on Thursday. Though the stock opened at $79.5, the bulls momentum made the stock top out at $80.69 level for the day. The stock recorded a low of $79.4 and closed the trading day at $80.59, in the green by 1.55%. The total traded volume for the day was 3,823,843. The stock had closed at $79.36 in the previous days trading.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.